立体定向放射外科治疗Koos IV级前庭神经鞘瘤的系统综述与Meta分析
该系统综述与Meta分析检索PubMed、Web of Science和Scopus,纳入10项研究共1398例患者,评估立体定向放射外科作为Koos IV级前庭神经鞘瘤主要治疗的效果。总体肿瘤控制率为90.7%(95%CI 86.3-94.4),面神经保留率100%(95%CI 99.9-100.0),但长期听力保留一般,并存在放射外科后脑积水风险。作者认为在适当选择的病例中放射外科可能有益,需进一步前瞻性研究直接比较放射外科与手术。
要点
- Koos IV级前庭神经鞘瘤放射外科后总体肿瘤控制率90.7%(95%CI 86.3-94.4)。
- 2、6、10年肿瘤控制率分别为96.0%、88.8%、84.5%。
- 面神经保留率100%(95%CI 99.9-100.0),三叉神经病发生率5.7%。
核心结论
- 系统综述与Meta分析显示放射外科治疗Koos IV级前庭神经鞘瘤总体肿瘤控制率高、面神经保留极好、新发或加重的耳鸣和眩晕发生率低。
- 但应注意放射外科相关缺点,包括放射外科后脑积水风险、长期听力保留一般以及缺乏立即的肿瘤减压。
- 作者认为在适当选择的Koos IV级前庭神经鞘瘤病例中放射外科可能有益。
- 作者指出需要进一步前瞻性研究直接比较放射外科与手术,以确定大前庭神经鞘瘤的最佳治疗并在更高证据水平上验证结果。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA声明,于2022年12月28日检索PubMed、Web of Science和Scopus,并于2023年9月7日更新检索。
- 使用NIH质量评估工具评估偏倚风险,使用R软件(版本4.3.2)进行所有定量分析和森林图制作。
- 共筛选2941条记录,最终纳入10项研究、1398例患者进行定量合成。
- 进行了发表偏倚和敏感性分析以评估所得结果的可靠性。
- 注册与方案编号:CRD42023389856。
主要发现
- 总体肿瘤控制率为90.7%(95%CI 86.3-94.4)。
- Kaplan-Meier估计的2年、6年和10年肿瘤控制率分别为96.0%(95%CI 92.9-97.6%)、88.8%(95%CI 86.9-89.8%)和84.5%(95%CI 81.2-85.8%)。
- 总体听力保留率为56.5%(95%CI 37-75.1);Kaplan-Meier估计的2年、6年和10年听力保留率分别为77.1%(95%CI 67.9-82.5%)、53.5%(95%CI 44.2-58.5%)和38.1%(95%CI 23.4-40.7%)。
- 总体面神经保留率为100%(95%CI 99.9-100.0);总体三叉神经病发生率为5.7%(95%CI 2.9-9.2)。
- 总体新发脑积水发生率为5.6%(95%CI 3-9);总体耳鸣加重或新发发生率为6.8%(95%CI 4.2-10.0),眩晕加重或新发发生率为9.1%(95%CI 2.1-19.6)。
临床怎么用
- 作者认为在适当选择的Koos IV级前庭神经鞘瘤病例中,使用放射外科可能有益。
- 作者指出需要进一步前瞻性研究直接比较放射外科与手术,以确定大前庭神经鞘瘤的最佳治疗并在更高证据水平上验证结果。
局限性
- 作者指出放射外科存在相关缺点,包括放射外科后脑积水风险、长期听力保留一般以及缺乏立即的肿瘤减压。
- 作者指出需要进一步前瞻性研究直接比较放射外科与手术,以确定大前庭神经鞘瘤的最佳治疗并在更高证据水平上验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic radiosurgery (SRS) is a well-established treatment option for Koos stage I-III vestibular schwannomas (VS), often used as the first line of treatment or after subtotal resection. However, the optimal treatment for Koos-IV VS remains unclear. Therefore, our study aimed to evaluate the effectiveness of SRS as a primary treatment for large VS classified as Koos-IV. METHODS: A systematic search was performed on December 28th, 2022, based on PubMed, Web of Science, and Scopus according to the PRISMA statement. The review was updated on September 7th, 2023. The risk of bias was assessed using the NIH Quality Assessment Tool. The R software (ver. 4.3.2) was used for all quantitative analyses and preparation of the forest plots. Publication bias and sensitivity analysis were performed to evaluate the reliability of the obtained results. RESULTS: Among 2941 screened records, ten studies (1398 patients) have been included in quantitative synthesis. The overall tumor control rate was 90.7% (95%CI 86.3-94.4). Kaplan-Meier estimates of tumor control at 2, 6, and 10 years were 96.0% (95% CI 92.9-97.6%), 88.8% (95% CI 86.9-89.8%), and 84.5% (95% CI, 81.2-85.8%), respectively. The overall hearing preservation rate was 56.5% (95%CI 37-75.1). Kaplan-Meier estimates of hearing preservation rate at 2, 6, and 10 years were 77.1% (95% CI 67.9-82.5%), 53.5% (95% CI 44.2-58.5%), and 38.1% (95% CI 23.4-40.7%), respectively. The overall facial nerve preservation rate was 100% (95%CI 99.9-100.0). The overall trigeminal neuropathy rate reached 5.7% (95%CI 2.9-9.2). The overall rate of new-onset hydrocephalus was 5.6% (95%CI 3-9). The overall rates of worsening or new-onset tinnitus and vertigo were 6.8% (95%CI 4.2-10.0) and 9.1% (95%CI 2.1-19.6) respectively. No publication bias was detected according to the used methods. CONCLUSIONS: Our systematic review and meta-analysis demonstrated a high overall tumor control rate, excellent facial nerve preservation, and low incidence of new-onset or worsened tinnitus and vertigo. However, several drawbacks associated with SRS should be noted, such as the presence of post-SRS hydrocephalus risk, mediocre long-term hearing preservation, and the lack of immediate tumor decompression. Nevertheless, the use of SRS may be beneficial in appropriately selected cases of Koos-IV VS. Moreover, further prospective studies directly comparing SRS with surgery are necessary to determine the optimal treatment for large VS and verify our results on a higher level of evidence. Registration and protocol: CRD42023389856.
引用
- Szymoniuk M, Kochański M, Wilk K, et al. Stereotactic radiosurgery for Koos grade IV vestibular schwannoma: a systematic review and meta-analysis. Acta Neurochir (Wien). 2024. PMID: 38393397. doi:10.1007/s00701-024-05995-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。